Propofol and children--what we know and what we do not know
Related Experiment Video
Updated: Jun 6, 2026

Guidelines for Elective Pediatric Fiberoptic Intubation
Published on: January 17, 2011
Ann E Rigby-Jones1, J Robert Sneyd
1Anaesthesia Research Group, Peninsula Medical School, Peninsula College of Medicine & Dentistry, University of Plymouth, Plymouth, UK. ann.rigby-jones@pms.ac.uk
Insights
Propofol pharmacokinetics are well-studied in children, with allometric scaling aiding predictions. However, pharmacodynamic data and pediatric anesthesia monitoring remain challenging, leaving key questions about children's sensitivity to propofol unanswered.
Area of Science:
- Anesthesiology
- Pharmacology
- Pediatric Medicine
Background:
- Propofol pharmacokinetics are well-established in pediatric populations.
- Allometric scaling is validated for predicting propofol disposition across species and pediatric development.
- Ontogenetic maturation in the first year of life necessitates adjustments to allometric models.
Purpose of the Study:
- To address the scarcity of pediatric propofol pharmacodynamic data.
- To investigate comparative sensitivity of children to propofol versus adults.
- To determine differences in time to peak effect in pediatric patients.
Main Methods:
- Utilized allometric scaling models for pharmacokinetic predictions.
- Employed time to peak effect techniques to determine K(eo) half-lives.
- Acknowledged limitations of current pediatric depth of anesthesia monitors.
Main Results:
- Allometric scaling models require specific adjustments for early infancy ontogeny.
- Pharmacodynamic data in children are limited due to practical and technological constraints.
- K(eo) half-lives for pediatric kinetic models have been determined.
Conclusions:
- Further research is needed to fully understand pediatric propofol pharmacodynamics.
- Current target-controlled infusion pumps do not incorporate determined pediatric K(eo) half-lives.
- Comparative sensitivity and time to peak effect in children remain areas for investigation.
Abstract:
The pharmacokinetics of propofol are relatively well described in the pediatric population. Recent work has confirmed the validity of allometric scaling for predicting propofol disposition across different species and for describing pediatric ontogenesis. In the first year of life, allometric models require adjustment to reflect ontogeny of maturation. Pharmacodynamic data for propofol in children are scarcer, because of practical difficulties in data collection and the limitations of currently available depth of anesthesia monitors for pediatric use. Hence, questions relating to the comparative sensitivity of children to propofol, and differences in time to peak effect relative to adults, remain unanswered. K(eo) half-lives have been determined for pediatric kinetic models using time to peak effect techniques but are not currently incorporated into commercially available target-controlled infusion pumps.
Related Concept Videos
Parenteral Anesthetics: Overview
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Inhalational Anesthetics: Overview
